mardi 30 septembre 2014

Targeted combination therapy halts disease, extends life in advanced melanoma patients

A world-first study heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic melanoma.

Targeted combination therapy halts disease, extends life in advanced melanoma patients

Aucun commentaire:

Enregistrer un commentaire